Phase 3Status unknown
Efficacy of Laflavon in Lowering Triglycerides and Raising High-Density Lipoprotein (HDL) (LaFlavon)
Trial of Laflavon in Patients With Metabolic Syndrome to Evaluate Its Effectiveness in Lowering Triglycerides and Raising High-Density Lipoprotein (HDL)
- Sponsor
- Omicron Pharmaceuticals (Industry)
- Enrolment
- 40 planned
- Conditions
- Metabolic Disease
- Interventions
- LaFlavon
- Ages
- adults, older adults
- Registry
- NCT01286909
Full record on ClinicalTrials.gov
From the registry
A trial of LaFlavon in Patients with Metabolic Syndrome to Evaluate its Effectiveness in Lowering Triglycerides and Raising High-Density Lipoprotein (HDL).
Primary outcomes
- Increase in High-Density Lipoprotein (HDL)
History
Primary completion
Last registry update
Registered
Started